Passage Bio, Inc. (PASG)
NASDAQ: PASG · Real-Time Price · USD
0.3572
-0.0238 (-6.25%)
Mar 31, 2025, 1:18 PM EDT - Market open
Passage Bio Stock Forecast
PASG's stock price has decreased by -70.92% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Passage Bio stock have an average target of 7.67, with a low estimate of 4.00 and a high estimate of 13. The average target predicts an increase of 2,047.26% from the current stock price of 0.36.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Passage Bio stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $7 → $6 | Strong Buy | Maintains | $7 → $6 | +1,579.73% | Mar 4, 2025 |
| Wedbush | Wedbush | Buy Initiates $4 | Buy | Initiates | $4 | +1,019.82% | Nov 29, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +1,859.69% | Nov 14, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +3,539.42% | Nov 14, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +3,539.42% | Sep 17, 2024 |
Financial Forecast
Revenue This Year
n/a
from 262.70M
Revenue Next Year
n/a
EPS This Year
-0.84
from -1.07
EPS Next Year
-0.79
from -0.84
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 141.8M | ||
| Avg | n/a | n/a | 45.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.81 | -0.57 | 0.19 | ||
| Avg | -0.84 | -0.79 | -0.13 | ||
| Low | -0.89 | -1.22 | -0.43 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.